Patients received 408 infusions of DMXAA over 19 dose levels from 6 to 4900 mg/m2, where dose-limiting toxicity was defined.
Building on the pre-clinical evidence for synergies between DMXAA and other cancer therapies, these results encourage us to go forward and explore the full potential of DMXAA in patients.
In January 2002, positive in vivo results were announced for DMXAA in combination with chemotherapy.
Higher research and development expenditure reflects the increased number of products in the development pipeline and manufacturing costs of Therex, AngioMab, Thioplatin and DMXAA to enable clinical studies to be conducted.
The studies were undertaken by the University of Auckland, New Zealand, to examine the effect of combining a single dose of DMXAA with single doses of nine widely-used chemotherapy agents in solid tumour in vivo models.
In the light of these findings, Antisoma plans to start a clinical study with DMXAA in combination with chemotherapy by the end of this year, following completion of a small dose-finding study in patients.
DMXAA is a small molecule that selectively restricts the blood flow through existing tumour blood vessels that feed tumour growth.
DMXAA has already completed two Phase I studies, and is being targeted initially for use in combination with chemotherapy.
Vascular targeting agents such as DMXAA have significant potential to selectively restrict the blood flow to a tumour that would otherwise feed its growth.
Vascular-targeting agent DMXAA in-licensed with Phase I data
Today we have announced a manufacturing agreement for DMXAA which will guarantee supplies of the product for further clinical trials.
Licensing agreements such as that for DMXAA
and the deal with the US National Institutes of Health for TheraNase announced today demonstrate our continued ability to find and exploit innovative products and technologies.